Breathing brief, moderate bouts of low oxygen trigger (low oxygen therapy, LOT) spinal plasticity (the ability of the nervous system to strengthen neural pathways based on new experiences), and improve walking after spinal cord injury (SCI). The greatest improvements in walking ability occur when LOT is administered prior to skill-based walking practice (WALK). However, the enduring benefits of LOT on walking recovery may be undermined by the accumulation of LOT-induced increase in extracellular adenosine. The goal of the study is to understand the extent to which istradefylline (adenosine 2a receptor antagonist) may limit the competing mechanisms of adenosine on LOT-induced walking recovery following SCI.

开始日期2024-09-01

申办/合作机构-

CTR20230645 / Recruiting临床3期

伊曲茶碱片用于改善左旋多巴治疗原发性帕金森病剂末现象的多中心、随机、双盲、安慰剂平行对照临床试验

评价伊曲茶碱片用于改善左旋多巴治疗原发性帕金森病剂末现象的有效性和安全性

开始日期2023-06-21

申办/合作机构

山东创新药物研发有限公司

NCT05885360 / Active, not recruiting临床4期IIT

Istradefylline Effect on Parkinson's Disease Tremor, Motor Symptoms and Non-motor Symptoms

This is an investigator-initiated trial. In this 6-month open label, single arm, exploratory pilot study, the investigator intends to enroll a pilot sample of 25 patients with Parkinson's disease who are being started on the novel FDA approved medication "Istradefylline'' as an add on therapy for management of their motor symptoms (based on the judgment of the movement disorders specialist, if patients are in sub-optimal management of their symptoms on maximum tolerable dose of their dopaminergic medications). The investigator will evaluate their motor symptoms before starting the new medication, including their MDS-UPDRS total and MDS-UPDRS-III scores.

开始日期2023-01-20

申办/合作机构

Georgetown University

[+1]

100 项与伊曲茶碱相关的临床结果

登录后查看更多信息

100 项与伊曲茶碱相关的转化医学

登录后查看更多信息

100 项与伊曲茶碱相关的专利（医药）

登录后查看更多信息

286

项与伊曲茶碱相关的文献（医药）

2024-03-01·eNeurologicalSci

Effect of istradefylline on postural abnormalities in patients with Parkinson's disease: An association study of baseline postural angle measurements with changes in Unified Dystonia Rating Scale total score

Article

作者: Shimokawa, Toshio ; Koh, Jinsoo ; Takeshima, Takao ; Takahashi, Makio ; Ito, Hidefumi ; Yamashita, Hirofumi ; Kajimoto, Yoshinori

In our previous study, istradefylline treatment in patients with Parkinson's disease (PD) improved postural abnormalities (PAs), as seen from a decrease in the mean Unified Dystonia Rating Scale (UDRS) total score from week 0 to week 24. A subgroup analysis based on baseline clinical characteristics investigated the association between improvement in the UDRS total score and istradefylline treatment. However, the association between an objective assessment of PAs and improvement in the UDRS total score is unclear. This ad hoc analysis investigated the association between improvement in the UDRS total score after istradefylline treatment and baseline trunk and neck angles, objective assessments of PAs, measured from patients' photographs taken in the previous study. The patients (n = 31) were stratified into groups based on the trunk forward flexion angle (TFFA), trunk lateral flexion angle (TLFA), and neck flexion angle (NFA) values at baseline. From week 0 to week 24, significant improvements in the UDRS total score were found in median percent change (-8.33% [interquartile range: -43.97, 0.00], P = 0.039) in patients with equal to or above the median TFFA values, and in median change (-‍1.50 [-9.25, 0.00], P = 0.015) and median percent change (-13.33% [-50.47, 0.00], P = 0.009) in patients with equal to or above the median TLFA values. Patients with more advanced PAs showed more consistent improvements in the UDRS total score with istradefylline. Baseline TFFA and TLFA values, which are objective values, may be useful to assess the istradefylline effectiveness in patients with PD and PAs.

2023-12-01·The mental health clinician

Management of OFF condition in Parkinson disease

Article

作者: Koch, Jessa

Abstract:

Parkinson disease (PD) impacts nearly 1 million individuals in the United States. Nearly every patient with PD will require therapy with dopamine in the form of levodopa as the disease progresses. In more advanced stages of the disease, patients will experience motor fluctuations and require adjustment to their medication regimens to maintain good control of their symptoms. During the last 10 years, several new therapeutic treatment options have come to the market to treat motor fluctuations and improve patient quality of life. Some of these agents represent additional options to previously available drug classes, such as the catechol-O-methyl transferase (COMT) inhibitor, opicapone, and monoamine-oxidase B-inhibitor (MAO-B inhibitor), safinamide, as well as new dosage forms for available therapeutics. One new agent, istradefylline, has a novel mechanism in the treatment of PD. The place in therapy for these newer therapeutic options will be explored through a series of patient cases. This article focuses on evidence-based recommendations for the use of these newer options in the management of patients experiencing OFF episodes.

2024-03-01·Neuroscience letters

Adenosine A2A receptor antagonist KW6002 protects against A53T mutant alpha-synuclein-induced brain damage and neuronal apoptosis in Parkinson's disease mice by restoring autophagic flux

Article

作者: Yuan, Jianshu ; Xu, Lingli ; Wang, Yuwen ; Liu, Xiaotian ; Hu, Qidi

BACKGROUND:

Protein misfolding and inclusion body aggregation caused by α-Syn mutations in the brain often cause neurodegeneration and cognitive impairment, among which the A53T point mutation is more common. Inhibition of adenosine A2A receptor (A_2AR) can alleviate the pathological symptoms of brain dysfunction caused by A53T-α-Syn protofibrils, but the mechanism of action is still unclear.

AIM:

This studies aimed to investigate the potential therapeutic role of the A_2AR inhibitor KW6002 in a mouse model of brain synucleinopathy.

METHODS:

A53T-α-Syn fibre precursor cell nuclear protein was injected into the bilateral prefrontal cortex of mice to establish a synucleinopathy animal model, and the A_2AR inhibitor KW6002 (5 mg/kg) was injected intraperitoneally to intervene.

RESULT:

The intracerebral injection of A53T-α-Syn protofibrils triggers the formation of inclusion bodies in the brain, leading to astrocyte activation, an increased number of apoptotic cells, and suppression of autophagic flux. The administration of KW6002 significantly reversed these phenomena. In vitro experiments revealed that A53T-α-Syn protofibrils inhibited HT-22 autophagy in mouse hippocampal neuronal cells, whereas KW6002 increased cellular autophagic flux, upregulated the expression of LAMP2A and Hsc70 proteins and inhibited the expression of SQSTM1 protein. The present study suggests that KW6002 reduces the level of α-Syn phosphorylation by inhibiting A_2AR protein, at the same time, enhances the autophagic flux of neuronal cells, resulting in the degradation of A53T-α-Syn protofibrils and thus reducing the neuronal toxicity and apoptosis induced by A53T-α-Syn protofibrils.

CONCLUSION:

KW6002 has a significant protective effect on neuronal injury induced by A53T-α-Syn.

项与伊曲茶碱相关的新闻（医药）

2024-05-22

·药精通Bio

美国FDA批准的38个小分子药合成路线汇总

深度聚焦多肽、多肽偶联药物研发、质控、工艺开发，联系电话181 1603 6798文章来源：有机合成路线这里小编和大家分享美国食品药品监督管理局 (FDA) 批准上市的38个化学小分子药合成路线，以飨化学和药化从业者，学生和爱好者。第一类（1.1）：抗肿瘤药物1.1.1 Erdafitinib (1)1.1.2 Alpelisib (2)1.1.3 Selinexor (3)1.1.4 Darolutamide (4)1.1.5 Pexidartinib (5)1.1.6 Entrectinib(6)1.1.7 Fedratinib (7)第二类（1.2）：抗菌药1.2.1 亚胺培南/西拉司丁/relebactam (9)1.2.2 Pretomanid (10)1.2.3 Lefamulin (11)1.2.4 Cefiderocol(12)第三类（1.3）：偏头痛治疗药物1.3.1 Lasmiditan (13)1.3.2 Ubrogepant(14)第四类（1.4）：其它治疗药物1.4.1 三氯苯达唑 (triclabendazole, 15)1.4.2 Brexanolone (16)1.4.3 Solriamfetol(17)1.4.4 Siponimod (18)1.4.5 Tafamidis(19) 和tafamidis meglumine1.4.6 Bremelanotide (20)1.4.8 替洛利生 (pitolisant, 22)1.4.9 Upadacitinib (23)1.4.10 Istradefylline (24)1.4.11Tenapanor(25)1.4.12 Trifarotene (26)1.4.13 阿法诺肽 (afamelanotide，27)1.4.14 Elexacaftor(28)/tezacaftor/ivacaftort1.4.15 Givosiran (29)1.4.16 Cenobamate (30)1.4.17 Voxelotor (31)1.4.18 Golodirsen (32)1.4.19Lemborexant (33)1.4.20 Lumateperone tosylate (34)2.1 Ga-68-DOTATOC(35)2.2 Fluorodopa (36)2.3 Air polymer-type A(37)是一种无菌透明凝胶 [polymer-type A(80.97 mg羟乙基纤维素 )，434.80 mg甘油 (85％)和纯净水 ]2.4 Brilliant blue G ophthalmic solution (38)参考文献：中国医药工业杂志Chinese Journal of Pharmaceuticals 2020, 51(1), 吕训磊，周伟澄，林快乐. 免责声明：本文信息来源于网络，本文仅作知识交流与分享及科普目的，不涉及商业宣传，不作为相关医疗指导或用药建议。文章如有侵权请联系删除。END深度聚焦多肽、多肽偶联药物研发、质控、工艺开发，7月相约苏州，联系电话18116036798戳“阅读原文”立即报名多肽药物论坛吧!

上市批准临床结果

2024-04-12

·PRNewswire

Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ® (istradefylline) and Other Parkinson's Disease Add-On Therapies

Findings to be presented at 2024 American Academy of Neurology annual conference between April 13-18 in Denver, CO PRINCETON, N.J., April 12, 2024 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, will announce findings from an updated systematic literature review (SLR) and meta-analysis comparing the safety of NOURIANZ® (istradefylline) in relation to other levodopa adjunctive therapies for patients with Parkinson's Disease (PD).1,2 NOURIANZ is an adenosine receptor antagonist used with levodopa/carbidopa to treat adults with PD experiencing "off" episodes, the return of Parkinson's symptoms between medication doses. The findings will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, during a poster presentation on Monday, April 15, from 5:30 – 6:30 PM MDT. Parkinson's disease is a progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, slow movement, and postural instability. Within 5 years of starting levodopa/carbidopa treatment, half of people living with PD begin to experience "off" time, including problems with movement.3 Adjunctive therapies may be used to treat these episodes but are often hampered by safety and tolerability issues that limit their clinical utility.1 "With the growing landscape of adjunctive therapies for Parkinson's disease, it is important for physicians to have data that demonstrates the relative risk profiles of these treatment options," said lead author Yasar Torres-Yaghi, MD, MedStar Georgetown University Hospital. "These data provide useful information on safety and tolerability of these therapies, an important factor for physicians when choosing an appropriate adjunctive therapy for patients experiencing "off" episodes." About the Study Researchers updated a previously published SLR with an additional 20 randomized controlled trials from Jan 1, 2010, to April 15, 2019, evaluating adjunctive therapies in patients with PD. The study analyzed data from a total of 57 randomized clinical trials involving 11,517 patients. Interventions included COMT inhibitors, monoamine oxidase type B (MAO-B) inhibitors, dopamine agonists (DAs), istradefylline, and amantadine ER. A pair-wise meta-analysis was conducted to calculate summary odds ratios (OR) and 95% confidence intervals (CI). Bucher indirect comparisons were used to generate estimates of relative safety, and information on study design, eligibility criteria, and baseline characteristics were extracted for heterogeneity assessment. About NOURIANZ® NOURIANZ is an adenosine receptor antagonist indicated as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes. It is not known if istradefylline is safe and effective in children.4 Important Safety Information Warnings and Precautions Dyskinesia: NOURIANZ in combination with levodopa may cause dyskinesia or exacerbate pre-existing dyskinesia. In clinical trials, 1% of patients treated with either NOURIANZ 20 mg or 40 mg discontinued treatment because of dyskinesia, compared to 0% for placebo. Hallucinations / Psychotic Behavior: Because of the potential risk of exacerbating psychosis, patients with a major psychotic disorder should not be treated with NOURIANZ. Consider dosage reduction or discontinuation if a patient develops hallucinations or psychotic behaviors while taking NOURIANZ. Impulse Control / Compulsive Behaviors: Patients treated with NOURIANZ and one or more medication(s) for the treatment of Parkinson's disease (including levodopa) may experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge or compulsive eating, and/or other intense urges, and the inability to control these urges. In clinical trials, 1 patient treated with NOURIANZ 40 mg was reported to have impulse control disorder, compared to no patient on NOURIANZ 20 mg or placebo. DRUG INTERACTIONS The maximum recommended dosage in patients taking strong CYP3A4 inhibitors is 20 mg once daily. Avoid use of NOURIANZ with strong CYP3A4 inducers. SPECIAL POPULATIONS Pregnancy: Based on animal data, may cause fetal harm. ADVERSE REACTIONS The most common adverse reactions with an incidence ≥5% and occurring more frequently than with placebo were dyskinesia (15%, 17%, and 8%), dizziness (3%, 6%, and 4%), constipation (5%, 6%, and 3%), nausea (4%, 6%, and 5%), hallucination (2%, 6%, and 3%), and insomnia (1%, 6%, and 4%) for NOURIANZ 20 mg, 40 mg, and placebo, respectively. You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-844-768-3544 or FDA at 1-800-FDA-1088 or . Please click to see full Prescribing Information for Nourianz. About Kyowa Kirin Kyowa Kirin aims to discover and deliver novel treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, focusing on bone/mineral, intractable hematological diseases/hemato oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe. You can learn more about the business of Kyowa Kirin at: kkna.kyowakirin.com References Torres-Yaghi Y., Qian, J. et al. (2024). Comparative Safety of Istradefylline Among Parkinson's Disease Adjunctive Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. Data presented at the 2024 American Academy of Neurology Annual Meeting, April 13-18, 2024, Denver, CO. Stowe R et al. Movement disorders. 2011;26(4):587-98 Hickey, P., & Stacy, M. (2011). Available and Emerging Treatments for Parkinson's Disease: A Review. Drug Design, Development and Therapy, 5, 241-254. doi:10.2147/DDDT.S11836 NOURIANZ. Prescribing Information. Kyowa Kirin Inc. Princeton, NJ. SOURCE Kyowa Kirin

临床结果临床研究

2024-04-12

·GBIHealth

帕金森：新疗法已在路上

帕金森病（Parkinson's disease，简称PD）帕金森病是仅次于阿尔茨海默病（AD）的第二大神经退行性疾病，于1817年由James Parkinson医生最早描述其症状，并以他的名字命名。作为常见的中老年神经系统退行性疾病，临床表现为震颤、肌强直、姿势平衡障碍等运动症状和睡眠障碍、自主神经功能障碍、认知和精神障碍等非运动症状，中晚期阶段常伴有运动并发症，严重影响患者的生活质量。变，万物随阳气上升而萌芽生长。 “ 据统计，全球范围内约有1000多万名患者饱受帕金森病的困扰。而我国的帕金森病患者人数预计将从2005年的199万人上升到2030年的近500万人，几乎占到全球帕金森病患病人数的一半。”发病机制帕金森的主要病理变化发生在中脑黑质腹侧的致密部，该区含有大量多巴胺神经元，患者致密部神经元大量死亡，有的甚至丧失高达70%的神经元，导致多巴胺的缺乏以及动作、边缘系统等神经回路的故障。二十世纪60年代研究发现，多巴胺前体化合物左旋多巴对帕金森症有治疗效果，直到今天仍是治疗帕金森的主力药物。然而，多巴胺制剂只能缓解帕金森症状，治标不治本，且副作用较大。后续研究发现，大脑黑质的病变与α-突触核蛋白有关，这种蛋白异常积聚，形成纤维蛋白沉淀并最终导致神经细胞死亡。α-突触核蛋白是可溶性蛋白，导致其异常聚集通常伴随着免疫激活、神经炎症、线粒体功能障碍以及溶酶体和内体功能的改变。研究者发现，这些病理过程与基因密切相关。比如，具有PRKN基因突变和主要线粒体功能障碍的患者表现出一种受限的细胞丧失模式，主要局限在黑质纹状体系统中，没有典型散发性帕金森病中所见的广泛病理和非运动特征。相反，具有SNCA或GBA突变，且α-突触核蛋白病理明显的患者在早期表现出非运动特征，包括自主神经功能障碍和痴呆，可能反映了全身和大脑中的广泛病理。这些风险基因不一定与α-突触核蛋白的病理直接相关。目前已经确定七个基因作为单基因病因，其中四个导致晚发性、常染色体显性遗传疾病（即LRRK2、CHCHD2、VPS35和SNCA），三个导致早发性、常染色体隐性遗传疾病（即PARKIN、DJ1和PINK1）。第八个基因GBA的变异是帕金森病的最常见遗传风险因素。未来有望开发出针对专门靶点的治疗药物。主要治疗思路流程除多巴胺制剂之外，儿茶酚-氧位-甲基转移酶抑制剂以及单胺氧化酶B型抑制剂也是帕金森的常用药物。根据《2020年中国帕金森病治疗指南》，对早发型、晚发型帕金森病，根据主要症状的不同选择不同的治疗方案（图1）。图1.患者用药选择流程图参考来源：《2020年中国帕金森病治疗指南》；DAs：多巴胺受体激动剂；MAO-BI：单胺氧化酶B型抑制剂；COMTI：儿茶酚-O-甲级转移酶抑制剂2020年指南继续强调了多学科治疗： ①坚持综合治疗，应对帕金森病的运动症状和非运动症状采取全面综合治疗；②强调多学科治疗模式，药物治疗仍为首选，并结合手术、运动与康复、心理干预等多种治疗手段；同时，提倡在临床条件允许的情况下，组建神经内科、功能神经外科、神经心理、康复乃至社区全科医生等多学科的医生团队；③明确全程管理，目前的治疗仍以改善症状为主，不能阻止病情的发展，治疗不仅立足当前，而且需长期管理，以达到长期获益。常见药物与在研新药根据传统治疗分类和在中国获批的药品，帕金森治疗药物主要有以下几种。复方左旋多巴：恩他卡朋双多巴、多巴丝肼多巴胺受体激动剂（DAs）：溴隐亭、培高利特（已撤市）、吡贝地尔、甲磺酸-a-二氢麦角隐亭、普拉克索、罗匹尼罗和罗替高汀儿茶酚-O-甲级转移酶抑制剂（COMTI）：托卡朋和恩他卡朋单胺氧化酶B型抑制剂（MAO-BI）：雷沙吉兰和司来吉兰抗胆碱药：苯甲托品、苯海索以及苯海拉明去甲肾上腺素前体：屈昔多巴神经保护剂：单唾液酸四己糖神经节苷脂钠此外，还有左旋多巴和卡比多巴，其中卡比多巴需与左旋多巴联用。帕金森领域进展较慢，从2010年至今，美国FDA批准的能用于缓解帕金森症状的新分子实体仅4款：Acadia Pharma 的5-羟色胺2A受体反向激动剂酒石酸匹莫范色林、US WorldMeds的沙非酰胺、协和发酵麒麟的A2A受体拮抗剂伊曲茶碱以及第三代强效COMTI奥匹卡朋。奥匹卡朋已有复星医药引进中国，目前正在进行临床试验。在国内进行开发的帕金森药品见下表。来源：GBI SOURCE新兴技术干细胞衍生药物治疗帕金森成为一条新的探索帕金森治疗的路径。继拜耳BlueRock之后，睿健医药成为国际第二家、国内首家提交帕金森领域多能干细胞衍生药物临床申请的公司。2022年4月28日，国家药监局受理了睿健医药自主研发的帕金森管线人源多巴胺能前体细胞注射液NouvNeu001的IND申请。临床前数据显示，通过睿健医药自研的高效化学小分子诱导功能细胞再生技术，NouvNeu001 移植入体内后可高效转化为成熟多巴胺能神经元，分泌多巴胺递质，并与体内原有神经元形成神经连接，产生综合性的治疗功能，改善帕金森症状。这类前体细胞除了能够分泌多巴胺这类递质之外，还可进一步分泌多种蛋白及小核酸来改善帕金森病灶，为移植到脑部的细胞发挥作用提供良好的“土壤”环境。企业交易活动国内对帕金森病的研究对比国际略显落后，因此一些企业开始引进海外的产品和技术。2018年1月，万邦生化（母公司复星医药）与葡萄牙公司BIAL达成合作，在中国大陆独家销售代理其帕金森病治疗药物奥吡卡朋；2020年10月，日本药企Kissei Pharmaceutical宣布已与中国生物医药公司AffaMed Therapeutics就其帕金森在研新药KDT-3594达成许可协议，Affamed Therapeutics将获得在大中华区（包括中国大陆、香港、澳门和台湾地区）和东南亚六国（包括新加坡，马来西亚，泰国，印尼，越南和菲律宾）开发和商业化KDT-3594（DAs）的独家权利;2021年4月，赛神医药与礼来达合作，获得在大中华区开发和商业化针对帕金森病α-突触核蛋白靶向疗法的权利；2022年3月，上海中泽医药与美国公司 Digestome Therapeutics达成合作，获得后者DGX-001在大中华市场的独家权利。DGX-001是一种全球首创口服治疗药物，可用于治疗精神分裂症的阴性症状和认知障碍，以及帕金森病的非运动症状；2022年3月，翼思生物与德国史达德大药厂（STADA Arzneimittel AG）子公司Brtiannia Pharmaceuticals Ltd签署了一项许可协议，获得在中国大陆、香港和澳门开发和商业其皮下注射阿扑吗啡用于帕金森病的独家权利；2023年5月，畅溪制药与美国公司Acorda Therapeutics达成合作，引进后者INBRIJA（左旋多巴吸入粉雾剂）在大中华地区（中国大陆及港澳台地区）的权利。INBRIJA已在美国和欧盟获批上市，用于正在接受左旋多巴-多巴脱羧酶抑制剂治疗的成年帕金森病患者，其在关闭期（OFF episodes）的间歇性治疗；2024年1月，斯坦福大学与先声药业达成合作研究协议，将共同推动一项神经系统领域的探索性研究，为帕金森患者研发创新疗法。帕金森发现至今，目前虽有多种可以缓解症状的疗法，但还没有一种能够延缓疾病进展或治愈疾病。未来，开发这一疾病更理想的治疗方法依然是医学领域的重要目标之一。\ | /★联系我们投稿 | 发稿 | 媒体合作▶ sylvia.hua@generalbiologic.com数据库 | 咨询服务 | 资讯追踪▶ 点击左下“阅读原文”完成表单填写点击阅读原文立即订阅相关报告

核酸药物

100 项与伊曲茶碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04641	伊曲茶碱	N04B	DB11757

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
帕金森病	日本	Kyowa Kirin Co., Ltd.	2013-03-25

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性帕金森病	临床3期	中国	石药集团中奇制药技术（石家庄）有限公司	2019-02-28
药物滥用	临床1期	美国	Kyowa Kirin Co., Ltd.	2016-01-01
肝病	临床1期	美国	Kyowa Kirin Co., Ltd.	2014-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


MDS2023	N/A	帕金森病 \| 肌张力失调	-	Istradefylline	窪獵糧糧餘夢壓簾醖餘(遞廠膚簾蓋鏇餘遞廠鏇) = 齋鬱糧簾餘選醖餘襯遞製範廠廠餘淵襯醖鹹衊 (積簾選鑰鹹淵獵壓獵餘 )	-	2023-08-27
				Istradefylline	窪獵糧糧餘夢壓簾醖餘(遞廠膚簾蓋鏇餘遞廠鏇) = 鑰鏇鹽衊艱壓膚醖壓願製範廠廠餘淵襯醖鹹衊 (積簾選鑰鹹淵獵壓獵餘 )
ISTRA ADJUST PD (MDS2022)	N/A	帕金森病	114	Istradefylline	繭範蓋鹽願糧鏇網壓蓋(夢鹽夢鑰艱窪範蓋蓋觸) = 繭積窪獵簾鏇積製遞鑰淵壓襯顧糧夢願構醖蓋 (選蓋願積製選糧選鹹餘 )	-	2022-09-15
				Control (no Istradefylline)	繭範蓋鹽願糧鏇網壓蓋(夢鹽夢鑰艱窪範蓋蓋觸) = 簾蓋構簾積憲淵衊築艱淵壓襯顧糧夢願構醖蓋 (選蓋願積製選糧選鹹餘 )
MDS2021	N/A	帕金森病 fasting glucose \| HbA1c \| insulin ... 更多	-	IST-LD combination group	膚夢齋蓋簾壓選網壓襯(膚壓選醖鹹鹹顧製遞獵) = 膚蓋鹽醖願糧構鹽膚憲遞網廠淵觸鑰衊醖選廠 (壓製餘膚蓋鹽壓糧憲觸 ) 更多	-	2021-09-17
				LD group	膚夢齋蓋簾壓選網壓襯(膚壓選醖鹹鹹顧製遞獵) = 糧蓋壓簾鑰餘膚壓願積遞網廠淵觸鑰衊醖選廠 (壓製餘膚蓋鹽壓糧憲觸 ) 更多
NCT01968031 (CTgov)	临床3期	帕金森病	613	Placebo (Placebo)	構獵鹽選鹽餘艱鹹蓋網(願淵艱鬱鹽壓糧構獵衊) = 衊築製製獵選構糧衊鏇襯鏇繭顧網窪壓網積積 (壓範衊憲憲願餘壓鹹觸, 糧鏇鹹衊網遞範願簾醖 ~ 廠簾齋鹹遞淵醖鬱衊觸) 更多	-	2020-11-20
				Placebo+Istradefylline 20 mg (Istradefylline 20 mg/Day)	構獵鹽選鹽餘艱鹹蓋網(願淵艱鬱鹽壓糧構獵衊) = 簾遞願憲淵憲蓋鬱廠顧襯鏇繭顧網窪壓網積積 (壓範衊憲憲願餘壓鹹觸, 鏇製齋顧醖簾遞艱醖壓 ~ 鏇鹹糧餘膚夢淵窪鹽糧) 更多
ANA2020	临床2/3期	-	1,160	Istradefylline 20 mg/day	顧繭衊膚築襯夢遞製衊(鑰鏇蓋膚簾遞繭壓選選) = The most common TEAE was dyskinesia (20 mg/day, 14.6%; 40 mg/day, 16.7%; placebo, 7.5%) 網網窪糧鹹範鑰網範艱 (積衊餘簾齋衊壓壓窪構 ) 更多	积极	2020-09-25
				Istradefylline 40 mg/day
pooled analysis of four pivotal randomized controlled trials of istradefylline (ANA2020)	临床3期	-	1,143	Istradefylline 20mg/day	繭衊繭夢網廠壓衊範膚(範獵顧網夢構蓋鹹窪願) = 夢襯廠選鹹淵鬱簾窪衊鬱製蓋築淵醖鬱淵鬱餘 (襯簾觸鏇鏇鏇淵選醖顧, -1.10 ~ -0.40) 更多	积极	2020-09-25
				Istradefylline 40mg/day	繭衊繭夢網廠壓衊範膚(範獵顧網夢構蓋鹹窪願) = 選蓋選襯鏇憲簾製憲醖鬱製蓋築淵醖鬱淵鬱餘 (襯簾觸鏇鏇鏇淵選醖顧, -1.17 ~ -0.47) 更多
MDS2020	N/A	-	31	Istradefylline 20 mg/day	積選鹹構窪憲獵遞積範(簾艱窪齋製襯襯憲壓壓) = 2 (6.5%) patients 築衊醖鑰觸鹹艱選餘餘 (鏇獵蓋膚製構艱繭範築 ) 更多	-	2020-09-12
				Placebo
MDS2020	临床2/3期	帕金森病	1,143	Istradefylline 20mg/day	願選網蓋窪範窪襯淵積(窪觸選鬱壓憲願積獵鑰) = Dyskinesia was the most frequent adverse event (20mg, 15%; 40mg, 17%; placebo, 8%) 鏇鹽遞廠願積夢衊艱糧 (範簾壓衊醖蓋鑰襯網鹹 )	积极	2020-09-12
MDS2020	N/A	帕金森病 hexokinase (HK-1) \| HK-2 \| insulin-like growth factor type 1 (IGF-1)	-	L-DOPA/IST combination therapy	糧餘獵衊襯積糧襯襯觸(築遞網夢顧膚衊鏇遞願) = depression 6.3 % 簾範觸製範夢醖憲鹽鹽 (網鑰製鹹衊獵憲壓壓鹽 ) 更多	-	2020-09-12
MDS2019	N/A	帕金森病	-	Istradefylline	網願鏇簾願鬱齋憲醖鹹(鬱鹹製齋憲鬱願選鹽範) = dyskinesia was the most frequent reported AE 遞製遞範鑰製鹽網齋範 (觸鬱繭壓艱鹽願蓋艱觸 )	积极	2019-09-22
				Placebo